NCT00571961 - Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

HIV Infections

Interventions

DRUG

Kaletra (lopinavir/ritonavir)

4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study

DRUG

buprenorphine

Buprenorphine will be obtained through prescription at the subject's drug treatment program.

OTHER

Clinical evaluations/Blood draws

Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.

Trial Locations (1)

06520

Yale University School of Medicine, New Haven